The abstract is read at the publisher; the summary is JClub's.
Spatial profiling of resected non-small cell lung cancer tumors and lymph nodes identified immune subtypes and a gene signature linked to improved outcomes.
- Why it matters: Neoadjuvant chemoimmunotherapy benefits resectable non-small cell lung cancer, but major pathologic response does not fully predict how durable that benefit will be.
- What they did: The study used spatial profiling of resected tumors and lymph nodes to define immune subtypes and derive a gene signature associated with outcomes.
- The result: The gene signature and immune subtype framework enable biomarker-guided treatment selection and support prospective validation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.